- Home
- BBD vs BIIB Comparison
BBD vs BIIB Comparison
Compare BBD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBD
- BIIB
- Stock Information
- Founded
- BBD 1943
- BIIB 1978
- Country
- BBD Brazil
- BIIB United States
- Employees
- BBD N/A
- BIIB N/A
- Industry
- BBD Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- BBD Finance
- BIIB Health Care
- Exchange
- BBD Nasdaq
- BIIB Nasdaq
- Market Cap
- BBD 24.0B
- BIIB 25.1B
- IPO Year
- BBD N/A
- BIIB 1991
- Fundamental
- Price
- BBD $2.06
- BIIB $162.00
- Analyst Decision
- BBD Buy
- BIIB Buy
- Analyst Count
- BBD 3
- BIIB 25
- Target Price
- BBD $3.20
- BIIB $258.57
- AVG Volume (30 Days)
- BBD 30.8M
- BIIB 1.7M
- Earning Date
- BBD 10-31-2024
- BIIB 10-30-2024
- Dividend Yield
- BBD 1.74%
- BIIB N/A
- EPS Growth
- BBD 8.84
- BIIB 10.05
- EPS
- BBD 0.25
- BIIB 11.06
- Revenue
- BBD $13,847,063,319.00
- BIIB $9,607,500,000.00
- Revenue This Year
- BBD N/A
- BIIB N/A
- Revenue Next Year
- BBD $10.66
- BIIB N/A
- P/E Ratio
- BBD $7.88
- BIIB $14.85
- Revenue Growth
- BBD 17.49
- BIIB N/A
- 52 Week Low
- BBD $2.02
- BIIB $153.62
- 52 Week High
- BBD $3.65
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- BBD 19.26
- BIIB 39.20
- Support Level
- BBD $2.02
- BIIB $158.44
- Resistance Level
- BBD $2.39
- BIIB $165.29
- Average True Range (ATR)
- BBD 0.06
- BIIB 4.02
- MACD
- BBD -0.03
- BIIB 1.10
- Stochastic Oscillator
- BBD 4.88
- BIIB 37.32
About BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. Banking provides roughly 70% of profits, while the insurance segment contributes the remaining 30%. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.